Inhibrx Biosciences (INBX) Free Cash Flow (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Free Cash Flow data on file, last reported at -$30.1 million in Q4 2025.

• On a quarterly basis, Free Cash Flow rose 29.57% year-over-year to -$30.1 million in Q4 2025; TTM through Dec 2025 was -$129.8 million, a 34.1% increase from a year earlier, with the FY2025 full-year figure at -$129.8 million, up 34.1% from the prior year.
• Free Cash Flow for Q4 2025 stood at -$30.1 million, up from -$33.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for INBX reached as high as -$29.9 million in Q2 2025 and fell as low as -$63.4 million in Q1 2024.
• Historically, Free Cash Flow has averaged -$44.2 million across 3 years, with a median of -$39.3 million in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 47.72% in 2025 and fell as far as 0.69% in 2025.
• Year by year, Free Cash Flow stood at -$60.3 million in 2023, then increased by 29.03% to -$42.8 million in 2024, then grew by 29.57% to -$30.1 million in 2025.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$30.1 million in Q4 2025, -$33.9 million in Q3 2025, and -$29.9 million in Q2 2025.